Sanofi Drops Amlitelimab: Second OX40L Eczema Failure

Sanofi (SNY) announced on July 24, 2026 that it will discontinue clinical development of amlitelimab in moderate-to-severe atopic dermatitis, deciding the drug would not represent a meaningful improvement over the current standard of care despite positive Phase 3 long-term extension data. The company will not submit the drug for global regulatory reviews.

SNY closed at $43.35 on July 24 with volume of 3.07 million shares.

What was killed

Amlitelimab is an OX40-ligand monoclonal antibody that blocks T-cell-mediated inflammation without depleting T-cells. The mechanism was once considered a potential next-wave approach to autoimmune disease. Sanofi acquired the asset through its $1.1 billion Kymab acquisition in 2021.

Phase 3 ESTUARY long-term extension data showed patients aged 12 and older maintained clinical response without relapse. The drug worked. But Sanofi concluded the efficacy and safety profile was not enough to justify a filing in a crowded eczema market dominated by its own Dupixent (dupilumab), which generated over $13 billion in 2025 revenue.

The OX40L class signal

Sanofi’s decision follows Kyowa Kirin’s discontinuation of rocatinlimab, another OX40L inhibitor, in atopic dermatitis. Two OX40L programs now shelved in the same indication suggests a class-level problem: the mechanism may not differentiate sufficiently from existing IL-4/IL-13 biologics like Dupixent.

The safety angle matters here. OX40L inhibitors modulate T-cell co-stimulation, which theoretically carries immunomodulatory risks distinct from cytokine-blocking biologics. While Sanofi reported no significant safety concerns in the ESTUARY long-term extension, the commercial risk is more pressing: Dupixent’s $13 billion revenue and entrenched formulary position leave little room for a me-too entrant that does not offer clear efficacy superiority.

This is a cautionary data point for investors evaluating pipeline depth. A drug can hit its endpoints and still not be worth filing if the competitive bar has moved.

What survives

A Phase 2 study of amlitelimab in celiac disease remains ongoing, with data expected in the second half of 2026. If that fails too, the asset is effectively dead. The celiac indication is a smaller market but has far fewer competing therapies, which could lower the efficacy bar for filing. Celiac disease also has no approved therapies, meaning any drug demonstrating meaningful benefit could capture the entire market. The OX40L mechanism may still find a niche in a less crowded indication where the efficacy bar is lower than in eczema, where Dupixent and Ebglyss have set a high standard.

What to watch next

Watch for Sanofi’s pipeline update at its next earnings call. The discontinuation reflects a broader strategic review under new CEO leadership. Sanofi said as recently as March that amlitelimab showed potential to be a meaningful treatment option, making this a notable reversal worth tracking for further pipeline cuts.

Source: Sanofi press release | FierceBiotech coverage | See our guide on how to invest in biotech.

What It Means for the Trade

The market read this correctly and moved on: a drug that works but cannot win is worth nothing, and Sanofi just proved it twice in one year with OX40L. For SNY holders, the investable question is not amlitelimab — it is what the pattern says about the rest of the pipeline. Under new leadership, assets are being killed on commercial-differentiation grounds before filing, which means the remaining pipeline list is a curated set rather than a wish list. That is healthy but painful: the €1 billion-plus of write-downs across the July cuts, plus this decision, confirm that the pre-review pipeline was carrying assets the market had valued at zero anyway.

The surviving trade is the celiac Phase 2 readout in the second half of 2026. Celiac has no approved therapies, so the efficacy bar is dramatically lower than eczema’s, and a win there converts a dead $1.1 billion Kymab acquisition into a first-in-indication asset. That is now the only optionality left in the molecule.

Mechanism and Market Context

The OX40L story is a class lesson in immunology’s complexity. Blocking OX40L was meant to dampen T-cell co-stimulation — upstream of the cytokine cascades — offering longer-lasting immune modulation than IL-4/IL-13 blockade. In the clinic, the mechanism produced maintained responses and clean safety, and it still wasn’t enough, because eczema’s standard of care had already been reset by Dupixent itself: a drug with a decade of real-world data, a familiar safety profile, and payer-preferred pricing. Rocatinlimab’s discontinuation by Kyowa Kirin removes the last direct read on whether the class could have differentiated with more time, but two shelvings in the same indication is a strong prior against it.

Risks and What Could Go Wrong

1. Celiac miss. If the Phase 2 celiac data disappoint, the entire Kymab OX40L spend is written off with nothing to show, and Sanofi’s pipeline depth narrative thins further.
2. Cut-chain overreach. A portfolio review this aggressive can kill assets the market would have valued; if a discarded program succeeds elsewhere, the credibility cost compounds.
3. Dupixent concentration. With each immunology cut, Sanofi’s near-term story concentrates harder on one $13 billion drug and its COPD expansion — single-asset risk in a mega-cap wrapper.
4. Read-through pressure. Every other company holding an OX40L-adjacent asset just took a negative class signal, and Sanofi’s own future mechanism bets will be judged against this kill discipline.

Net: correct kill, contained damage, one live option left in celiac. Watch the H2 2026 celiac readout; otherwise this story is closed.